Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-C19 + Atezolizumab in Refractory DLBCL (ZUMA-6)
NCT02926833Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Sep 2016
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of axicabtagene ciloleucel and atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Primary endpoints: Dose-Limiting Toxicities at 21 days and Complete Response Rate up to 6.2 years. Started Sep 2016; status: completed.
02
Drugs
axicabtagene ciloleucelatezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02926833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926833.